SEC Tracker
Get the app

Possible new DTIL shares

DTILDilution

Known so far: no new shares from the prospectus covers read · shelf room about $15.7M · not yet read: converts, ATM.

Shelf room

  • Room today about $15.7M
  • One third of float $15.7M ($47.1M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $15.7M on the S-3 of Dec 30, 2025: the baby-shelf rule (public float under $75M) caps sales at one third of the $47.1M public float stated as of Jun 30, 2025, $15.7M, nothing sold off it in the last 12 months. Sources: S-3 Dec 30, 2025, effective Jan 7, 2026 · public float, as of Jun 30, 2025.

What could become new Precision Biosciences (DTIL) shares: warrants and options and RSUs, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

DTIL dilution ladder

Every source of new shares on record, from the filings that created it.

27.9M outstanding; up to 31.6M fully diluted, +13%

  1. Outstandingas of Oct 29, 2026 (10-Q filed Nov 3) · share count on the cover page
    27.9M
  2. Warrants465K10-Q Nov 3, 2026 · securities left out of diluted EPS
    +465K
  3. Options and RSUs146K options, 3M RSUs10-Q Nov 3, 2026 · equity note
    +3.2M

Not stated in the filings we read: an ATM program, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Nov 3, 2026.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

27.9M

Mar 2025 to Oct 2026: from 10.5M to 27.9M.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.